Ammonia Solution, Strong

Ammonia Solution, Strong

SCHEMBL25173399

CCCCCCCc1ccc([C@H]2C[C@H]2CCC(=O)N(CCOP(=O)(O)O)Cc2ccc(OC)cc2)cc1.N

nearest known ligand 0.44

Full drug profile on Sugi Atlas →

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ S1PR4 O95977 9/20 0.44
▸ S1PR5 Q9H228 8/20 0.44
▸ CTSD P07339 1/20 0.37
▸ S1PR1 P21453 6/20 0.37
▸ S1PR3 Q99500 6/20 0.37
▸ S1PR2 O95136 2/20 0.37
▸ BCHE P06276 1/20 0.37
▸ ACHE P22303 1/20 0.37
▸ ALOX5 P09917 1/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ CA12 O43570 1/20 0.36
▸ CA1 P00915 1/20 0.36
▸ CA2 P00918 1/20 0.36
▸ CA9 Q16790 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ammonia Solution, Strong SCHEMBL25175624 1.00 S1PR4 (0.44) S1PR4S1PR5CTSDS1PR1S1PR3
SCHEMBL25456774 0.99 S1PR4 (0.45) S1PR4S1PR5CTSDS1PR1S1PR3
SCHEMBL25456775 0.99 S1PR4 (0.45) S1PR4S1PR5CTSDS1PR1S1PR3
SCHEMBL25175803 0.89 S1PR4 (0.37) S1PR4S1PR5CTSDBCHEACHE
Ammonia Solution, Strong SCHEMBL25175634 0.86 ALOX5 (0.47) S1PR4S1PR5S1PR1S1PR3S1PR2
Ammonia Solution, Strong SCHEMBL25167613 0.84 ALOX5 (0.47) S1PR4S1PR1S1PR3S1PR2BCHE
SCHEMBL25456795 0.83 ALOX5 (0.48) S1PR4S1PR1S1PR3S1PR2BCHE
Ammonia Solution, Strong SCHEMBL25175641 0.82 S1PR4 (0.39) S1PR4S1PR5CTSDS1PR1S1PR3
Ammonia Solution, Strong SCHEMBL25175642 0.82 S1PR4 (0.39) S1PR4S1PR5CTSDS1PR1S1PR3
SCHEMBL25456786 0.81 S1PR4 (0.39) S1PR4S1PR5CTSDS1PR1S1PR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11802135-B2 Lysophosphatidic acid derivative MITSUBISHI TANABE PHARMA CORPORATION (JP) 2023-10-31 — — US disclosed
US-20230146210-A1 NOVEL LYSOPHOSPHATIDIC ACID DERIVATIVE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2023-05-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11802135-B2 Lysophosphatidic acid derivative LPAR4, LPAR2, LPAR1 S1PR4 12/4885S1PR5 21/4885CTSD 2648/4885
US-20230146210-A1 NOVEL LYSOPHOSPHATIDIC ACID DERIVATIVE LPAR4, LPAR2, LPAR1 S1PR4 12/4885S1PR5 21/4885CTSD 2982/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback